## Etienne De Braekeleer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9411783/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature, 2017, 552, 126-131.	27.8	833
2	A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Reports, 2016, 17, 1193-1205.	6.4	556
3	Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature, 2021, 593, 597-601.	27.8	531
4	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell, 2018, 23, 700-713.e6.	11.1	272
5	METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell, 2021, 81, 3323-3338.e14.	9.7	153
6	UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nature Genetics, 2018, 50, 883-894.	21.4	117
7	SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature Communications, 2018, 9, 5378.	12.8	60
8	3q26/ <i>EVI1</i> rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncology, 2015, 11, 1675-1686.	2.4	28
9	KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia, 2021, 35, 1012-1022.	7.2	26
10	Prognostic impact of <i>p15</i> gene aberrations in acute leukemia. Leukemia and Lymphoma, 2017, 58, 257-265.	1.3	10
11	SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD–mutant AML. Blood Advances, 2021, 5, 2412-2425.	5.2	10
12	Cytogenetic Resources and Information. Methods in Molecular Biology, 2017, 1541, 311-331.	0.9	1